Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669745 · ClinicalTrials.gov registry record
The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients
A clinical trial, sponsored by Agendia.
- Completed
- Registry status
- 64
- Enrollment target
NCT02669745: Completed study, sponsored by Agendia.
NCT02669745 is a clinical trial that has completed, run by Agendia. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02669745 has completed, sponsored by Agendia.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
This study is experimental and will prospectively assess the proportion of patients in the two (2) MammaPrint Risk categories in patients of Chinese descent.
Primary Outcome
The MammaPrint risk assessment outcomes will be compared with conventionally used risk assessments determined by clinical parameters, standard staging and IHC analysis (Adjuvant! Online) in a population of Chinese patients with breast cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-01 |
| Est. Completion | 2019-05 |
What the finished NCT02669745 record still lists
NCT02669745 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02669745 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02669745 about?
NCT02669745 is a clinical study titled "The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients". This study is experimental and will prospectively assess the proportion of patients in the two (2) MammaPrint Risk categories in patients of Chinese descent.
What is the current status of trial NCT02669745?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2012-01. Estimated completion is 2019-05.
Who is sponsoring clinical trial NCT02669745?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia